Core Viewpoint - A class action lawsuit has been filed against Rocket Pharmaceuticals, alleging violations of the Securities Exchange Act of 1934 related to misleading information about the company's clinical trials and safety protocols [1][4][5]. Company Overview - Rocket Pharmaceuticals operates as a late-stage biotechnology company focused on developing gene therapies for rare and devastating diseases [3]. Allegations of the Lawsuit - The lawsuit claims that Rocket Pharmaceuticals provided investors with misleading information regarding the Phase 2 pivotal trial of RP-A501 for Danon disease, while concealing material adverse facts about the safety and clinical trial protocol [4]. - It is alleged that the company failed to disclose serious adverse events, including participant deaths, and made substantive amendments to the trial protocol without informing shareholders [4][5]. - Following the announcement of a clinical hold by the U.S. Food and Drug Administration due to a serious adverse event, the stock price of Rocket Pharmaceuticals reportedly fell [5]. Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Rocket Pharmaceuticals securities during the class period to seek appointment as lead plaintiff in the lawsuit [6]. - The lead plaintiff represents the interests of all class members and can select a law firm to litigate the case [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [7].

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, July 28, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Rocket Pharmaceuticals, Inc. ("Rocket Pharmaceuticals" or the "Company") (NASDAQ: RCKT) investors of a class action representing investors that bought securities between February 27, 2025 and May 26, 2025, inclusive (the "Class Period"). Rocket Pharmaceuticals investors have until August 11, 2025 to file a lead plaintiff motion. Investors are e ...

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Rocket investors who were adversely affected by alleged securities fraud between February 27, 2025 and May 26, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/rocket-pharmaceuti ...

ATLANTA, July 28, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed Rocket Pharmaceuticals, Inc. (“Rocket Pharmaceuticals” or the “Company”) (NASDAQ: RCKT). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to adequately disclose that Rocket Pharmaceuticals knew Serious Adverse Events (SAEs), including death of participants enrolled in the study, were a risk. If you purchased shares of Rocket Pharmaceuticals between February 27, 202 ...

NEW YORK, July 28, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT).Shareholders who purchased shares of RCKT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/rocket-pharmaceuticals-inc-loss-submission-form/?id=158122&from=4CLASS PERIO ...

SAN DIEGO, July 26, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that the Rocket Pharmaceuticals class action lawsuit – captioned Ho v. Rocket Pharmaceuticals, Inc., No. 25-cv-10049, and pending in the District of New Jersey – seeks to represent purchasers or acquirers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities and charges Rocket Pharmaceuticals as well as one of Rocket Pharmaceuticals’ executives with violations of the Securities Exchange Act of 1934. A ...

NEW YORK, July 25, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Rocket investors who were adversely affected by alleged securities fraud between February 27, 2025 and May 26, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/rocket-pharmaceuti ...

Core Viewpoint - Rocket Pharmaceuticals is undergoing a strategic reorganization to extend its operational runway and focus on its adeno-associated virus (AAV) cardiovascular platform, which includes several clinical programs [1][2][3]. Group 1: Corporate Reorganization - The restructuring initiative will prioritize resources on clinical programs for Danon disease, PKP2-associated arrhythmogenic cardiomyopathy, and BAG3-associated dilated cardiomyopathy, while also addressing the complete responses to the CRL for KRESLADI [2][3]. - The company plans to reduce its workforce by approximately 30%, which, along with other cost-saving measures, is expected to decrease 12-month operating expenses by nearly 25% [3]. Group 2: Financial Outlook - Rocket anticipates that its existing cash resources will fund operations into the second quarter of 2027 [3]. - Analyst Jason Zemansky from Bank of America downgraded Rocket from Buy to Neutral and reduced the price forecast from $9 to $4, citing weakened investor confidence due to recent failures in the gene therapy sector [5][6]. Group 3: Program Delays and Regulatory Challenges - The company expects delays in the Fanconi Anemia and Pyruvate Kinase Deficiency programs, with regulatory approval for RP-L102 in 2026 now deemed unlikely [4]. - A clinical hold was placed by the FDA on the Phase 2 pivotal trial of RP-A501 for Danon disease, further complicating the company's outlook [4].

NEW YORK, July 24, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). Shareholders who purchased shares of RCKT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/rocket-pharmaceuticals-inc-loss-submission-form/?id=157787&from=3 CLA ...

Danon disease is a multi-organ lysosomal-associated disorder leading to early death due to heart disorder. SAN FRANCISCO, July 23, 2025 (GLOBE NEWSWIRE) -- When, on May 27, 2025, Rocket Pharmaceuticals (NASDAQ: RCKT) revealed that the FDA put a clinical hold on its Phase 2 pivotal trial for RP-A501, an experimental therapy intended to treat patients with a rare gene disorder called Danon disease, investors in the company's shares saw their investment crash over 60% that day. The company's narrative unravele ...